Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial.

Abstract

RATIONALE Bronchiectasis is characterised by excessive production of mucus and pulmonary exacerbations. Inhaled osmotic agents may enhance mucociliary clearance, but few long-term clinical trials have been conducted. OBJECTIVES To determine the impact of inhaled mannitol on exacerbation rates in patients with non-cystic fibrosis (CF) bronchiectasis… (More)
DOI: 10.1136/thoraxjnl-2014-205587

Topics

7 Figures and Tables

Cite this paper

@article{Bilton2014InhaledMF, title={Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial.}, author={Diana Bilton and Gregory Tino and Alan F. Barker and Daniel C Chambers and Anthony De Soyza and L. Dupont and Conor S O'Dochartaigh and Eric H J van Haren and Luis Vidal and Tobias Welte and Howard G. Fox and Jian Wu and Brett Charlton}, journal={Thorax}, year={2014}, volume={69 12}, pages={1073-9} }